St. Joseph's Laboratory & Donor Center - Pavillion Building

With offices adjacent to Children's Hospital of Orange County (CHOC) in Orange and CHOC at Mission, we are conveniently located for your patients and their families. Our number one priority and passion at Pediatric Surgical Associates is to care for our community’s kids...

Dr. Hoyle has been practicing Phlebology (Specialty with Vein Disorders) for 15 years. He was the first physician in Orange County to perform endovenous laser ablations. He was also the first doctor to perform micro phlebectomy and the first to utilize tumescent anesthesia for vein procedures. He has been an invited lecturer at Chapman University and appeared twice on the TV show "Health Matters". He has also been interviewed on the radio show "Straight Talk MD". Dr. Hoyle is an expert reviewer for the Medical Board of California and served for several years as a consultant at the VA hospital in Long Beach. Dr. Hoyle was among the first 200 doctors in the U.S. to pass the exam to obtain Certification by the American Board of Lymphatic and Venous Medicine. He has also passed the examination for Registered Physician in Vascular Interpretation (R.P.V.I.) by the American Registry for Diagnostic Medical Sonography.A Canadian transplant from Toronto, with a medical degree from the University of Western Ontario, Bruce Hoyle has lived and worked in Orange County, California for most of his career. He holds an MBA degree from the University of California, Irvine. Dr. Hoyle is the chairman of the ACP's Coding and Reimbursement Committee and serves on the American Medical Association's CPT Advisory Panel. He has also served on the board of the ACP Foundation.In 2012 Dr. Hoyle was elected a "Fellow" of the American College of Phlebology.In 2013 Dr. Hoyle wrote a chapter revision in the American College of Phlebology's textbook "Fundamentals of Phlebology."In 2013 he completed a white paper for the American College of Phlebology, "Guidelines for Treatment of Superficial Venous Disease". This document was produced mainly for the insurance industry in the hope of creating more uniformity to medical necessity for treatment of superficial venous disease. In 2015 he spoke to Medicare Administrators for 12 states regarding coverage of the Clarivein device (mechanochemical ablation). Recently he agreed to serve as an advisor to the AMA CPT editorial panel.